Milestone Appoints David Sandoval As General Counsel Amid CARDAMYST Launch Strengthens Leadership With New Legal Chief

Milestone Pharmaceuticals has named David Sandoval as its new General Counsel and Chief Compliance Officer, strengthening its executive team as the company rolls out its newly approved product, CARDAMYST™ (etripamil) nasal spray. CARDAMYST became the first self-administered therapy cleared by the U.S. FDA in December 2025 for rapidly converting acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to normal heart rhythm in adults.

In his new role, Sandoval will oversee Milestone’s legal and compliance strategy across the organization, supporting areas such as corporate governance, contracts, finance, investor relations, intellectual property, business development and human resources.

“David’s appointment strengthens our leadership team at a critical stage for Milestone as we execute on the launch of CARDAMYST,” said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals. “His extensive experience leading legal and compliance teams and supporting commercial launches in highly regulated environments will be invaluable as we scale our operations and build the infrastructure to support long-term growth. I welcome David to Milestone and look forward to his impactful contributions.”

Sandoval brings more than 15 years of life-sciences legal leadership, with deep experience in regulatory approvals, late-stage development and first-product launches. He has advised boards and executive teams on SEC compliance and built comprehensive healthcare compliance programs covering promotional review, interactions with healthcare professionals, pricing and market access, Sunshine Act reporting and enterprise risk management.

Most recently, he served as Senior Vice President and General Counsel at MaxCyte, where he led global legal and compliance operations and supported major strategic transactions, including the acquisition of SeQure Dx. Earlier, he was Chief Legal Officer for North America at Leadiant Biosciences, where he established the company’s U.S. legal and compliance infrastructure and guided multiple product launches and asset transactions. 

Mr. Sandoval said, “I am very excited to join Milestone at this important time. I look forward to partnering with the leadership team to further build upon a strong legal and compliance foundation that will enable successful commercialization, support long-term growth and help drive value creation for shareholders, and continue to benefit the patients we serve.”

Sandoval previously held senior roles at Enzon Pharmaceuticals and Eisai, advising on FDA regulatory matters, marketing compliance and fraud-and-abuse laws, and began his legal career at O’Melveny & Myers LLP. He holds a law degree from NYU, a bachelor’s degree from Cornell University, and a business administration certificate from Georgetown University.